AKERO THEREP.INC.DL-0001
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunct… Read more
Market Cap & Net Worth: AKERO THEREP.INC.DL-0001 (0K4)
AKERO THEREP.INC.DL-0001 (F:0K4) has a market capitalization of $3.93 Billion (€3.83 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #3673 globally and #347 in its home market, demonstrating a -0.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AKERO THEREP.INC.DL-0001's stock price €46.53 by its total outstanding shares 82316179 (82.32 Million).
AKERO THEREP.INC.DL-0001 Market Cap History: 2019 to 2025
AKERO THEREP.INC.DL-0001's market capitalization history from 2019 to 2025. Data shows growth from $1.77 Billion to $3.93 Billion (11.74% CAGR).
AKERO THEREP.INC.DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AKERO THEREP.INC.DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0K4 by Market Capitalization
Companies near AKERO THEREP.INC.DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to AKERO THEREP.INC.DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
AKERO THEREP.INC.DL-0001 Historical Marketcap From 2019 to 2025
Between 2019 and today, AKERO THEREP.INC.DL-0001's market cap moved from $1.77 Billion to $ 3.93 Billion, with a yearly change of 11.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €3.93 Billion | +73.30% |
| 2024 | €2.27 Billion | +24.31% |
| 2023 | €1.83 Billion | -56.80% |
| 2022 | €4.22 Billion | +167.38% |
| 2021 | €1.58 Billion | -8.33% |
| 2020 | €1.72 Billion | -2.86% |
| 2019 | €1.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AKERO THEREP.INC.DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.93 Billion USD |
| MoneyControl | $3.93 Billion USD |
| MarketWatch | $3.93 Billion USD |
| marketcap.company | $3.93 Billion USD |
| Reuters | $3.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.